Clinical Trials Logo

Oncology Patients clinical trials

View clinical trials related to Oncology Patients.

Filter by:

NCT ID: NCT04406844 Recruiting - Oncology Patients Clinical Trials

Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic

Start date: May 9, 2020
Phase:
Study type: Observational

In view of increasing cases of SARS-CoV-2 leading to the COVID-19 Pandemic in India,there has been unprecedented restrictions on travel, work and other aspects of daily life. Our study has been designed to collect data of cancer patients to analyze their issues and challenges during Covid-19 Pandemic.

NCT ID: NCT02437916 Terminated - Cancer Clinical Trials

Safety Study of AMG 228 to Treat Solid Tumors

Start date: April 21, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

NCT ID: NCT02110355 Completed - Cancer Clinical Trials

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Start date: December 19, 2014
Phase: Phase 1
Study type: Interventional

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

NCT ID: NCT02016729 Completed - Cancer Clinical Trials

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Start date: April 1, 2014
Phase: Phase 1
Study type: Interventional

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

NCT ID: NCT01723020 Completed - Cancer Clinical Trials

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Start date: December 27, 2012
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

NCT ID: NCT01444404 Completed - Cancer Clinical Trials

A Study of AMG 820 in Subjects With Advanced Solid Tumors

Start date: March 31, 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.

NCT ID: NCT01300026 Completed - Cancer Clinical Trials

AMG 319 Lymphoid Malignancy FIH

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This is a multi-center, phase 1, open-label first-in-human study of AMG 319 in subjects with relapsed or refractory lymphoid malignancies. This study consists of two parts. The dose exploration in part 1, studies cohorts of 3 subjects with relapsed or refractory lymphoid malignancies and uses a practical continuous reassessment model [CRM] to guide dose escalation and to define the MTD. The dose expansion in part 2 will enroll 20 subjects with CLL at a dose no higher than the MTD and further explore the safety, PK, and clinical activity of AMG 319 in this patient population.

NCT ID: NCT01253707 Completed - Cancer Clinical Trials

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Start date: December 8, 2010
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 337 in subjects with advanced solid tumors.

NCT ID: NCT01231347 Terminated - Cancer Clinical Trials

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

GAMMA
Start date: April 2011
Phase: Phase 3
Study type: Interventional

AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. Gemcitabine is administered on days 1, 8 and 15 of a 28 day cycle, AMG 479 or placebo is administered on days 1 and 15 of the 28 day cycle, both are administered intravenously. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.

NCT ID: NCT00813384 Completed - Cancer Clinical Trials

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Start date: December 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.